지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.1
- 수록면
- 270 - 278 (9page)
이용수
초록· 키워드
오류제보하기
Treat-to-target (TTT) for osteoporosis is a concept for individualizing patient treatment decisions that focuses on achieving an acceptable level of fracture risk rather than response to treatment alone. While a response to treatment is essential in order to achievean acceptable level of risk, it is not necessarily sufficient. Some patients have a good response to treatment yet remain at high levelof fracture risk. Since there is no way to directly measure bone strength in patients treated for osteoporosis, a surrogate measurementmust be used. Bone mineral density (BMD) is commonly used to select patients for treatment and has emerged as the most usefulsurrogate for assessing reduction of fracture risk after treatment is started. Recent large meta-regression studies have shown a robustcorrelation between larger increases in BMD with treatment and greater reductions in fracture risk. Application of TTT for osteoporosis involves assessing fracture risk before starting treatment and initiating treatment with an agent that is most likely to reduce fracture risk to an acceptable level, represented by a target BMD T-score, over a reasonable period of time. This review offers suggestions for implementing TTT for osteoporosis in clinical practice and managing patients who fail or succeed in reaching the target. More study is needed to fully validate the use of TTT for osteoporosis for initiating and modifying treatments to reduce fracture risk.
목차
등록된 정보가 없습니다.
참고문헌 (43)
참고문헌 신청
Verdecchia P / 2020 / The 2020 International Society of Hypertension global hypertension practice guidelines : key messages and clinical considerations / Eur J Intern Med 82:1~6
American Diabetes Association / 2020 / 6. Glycemic targets : standards of medical care in diabetes-2020 / Diabetes Care 43(Suppl 1):S66~76
Smolen JS / 2020 / EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update / Ann Rheum Dis 79:685~699
NIH Consensus Development Panel on Osteoporosis Prevention / 2001 / Osteoporosis prevention, diagnosis, and therapy / JAMA 285:785~795
Khosla S / 2012 / Benefits and risks of bisphosphonate therapy for osteoporosis / J Clin Endocrinol Metab 97:2272~2282
American Diabetes Association / 2020 / 6. Glycemic targets : standards of medical care in diabetes-2020 / Diabetes Care 43(Suppl 1):S66~76
Smolen JS / 2020 / EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update / Ann Rheum Dis 79:685~699
NIH Consensus Development Panel on Osteoporosis Prevention / 2001 / Osteoporosis prevention, diagnosis, and therapy / JAMA 285:785~795
Khosla S / 2012 / Benefits and risks of bisphosphonate therapy for osteoporosis / J Clin Endocrinol Metab 97:2272~2282
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Environmental Air Pollution and the Risk of Osteoporosis and Bone Fractures
예방의학회지
2018 .01
-
Environmental Air Pollution and the Risk of Osteoporosis and Bone Fractures
예방의학회지
2018 .01
-
Treatment of Osteoporosis: Unmet Needs and Emerging Solutions
대한골대사학회지
2018 .01
-
Factors associated with osteoporosis medication initiation and adherence
Osteoporosis and Sarcopenia
2018 .01
-
Introduction of the Cost-Effectiveness Studies of Fracture Liaison Service in Other Countries
대한골대사학회지
2020 .01
-
Medical treatment of severe osteoporosis including new concept of advanced severe osteoporosis
Osteoporosis and Sarcopenia
2016 .01
-
Up-to-Date Knowledge on Osteoporosis Treatment Selection in Postmenopausal Women
대한폐경학회지
2022 .12
-
Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
Osteoporosis and Sarcopenia
2017 .01
-
A coordination project for improvement of osteoporosis medication use among patients who sustained osteoporotic fracture(s)
Osteoporosis and Sarcopenia
2019 .01
-
Osteoporosis treatment rates after hip fracture 2011?2019 in Hawaii: Undertreatment of men after hip fractures
Osteoporosis and Sarcopenia
2021 .09
-
Surgical treatment of severe osteoporosis including new concept of advanced severe osteoporosis
Osteoporosis and Sarcopenia
2017 .01
-
남성 골다공증의 위험 요인에 대한 최신 지견과 공중보건학적 중재 전략
보건교육건강증진학회지
2023 .06
-
Prevalence of osteoporosis in elderly women in Hong Kong
Osteoporosis and Sarcopenia
2021 .09
-
Relationship between Decrease in Serum Sodium Level and Bone Mineral Density in Osteoporotic Fracture Patients
대한골대사학회지
2015 .01
-
Best Laboratory Screening in Diagnosing Secondary Osteoporosis and Fracture Risk Assessment Tool and the National Osteoporosis Guideline Group Performance in Determining Clinical Risk: A Cross-Sectional Evaluation of the Bone Health in Postmenopausal Brazilian Women
대한골대사학회지
2023 .02
-
10-Year Fracture Risk in Postmenopausal Women with Osteopenia and Osteoporosis in South Korea
Endocrinology and Metabolism
2021 .12
-
Bone Health Evaluations and Secondary Fragility Fractures in Hip Fracture Patients
Hip and Pelvis
2024 .03
-
Is ankle fracture related to low bone mineral density and subsequent fracture? A systematic review
Osteoporosis and Sarcopenia
2020 .01
-
A Prediction Model for Osteoporosis Risk Using a Machine-Learning Approach and Its Validation in a Large Cohort
Journal of Korean Medical Science
2023 .05
-
Health-related Quality of Life in Accordance with Fracture History and Comorbidities in Korean Patients with Osteoporosis
대한골대사학회지
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0